/AKBLF
AKBLF Stock - ALK-Abelló A/S
Healthcare|BiotechnologyOTC
$35.45-1.92%
$0.69 (-1.92%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.87
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.92
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $39.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AKBLF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$35.10 – $35.80
TARGET (TP)$40.77
STOP LOSS$32.61
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.70
52W High$36.14
52W Low$19.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.54B | $4.82B | $4.51B | $3.92B | $3.49B |
| Gross Profit | $3.55B | $3.04B | $2.79B | $2.40B | $2.03B |
| Gross Margin | 64.2% | 62.9% | 61.9% | 61.3% | 58.1% |
| Operating Income | $1.09B | $666.00M | $470.00M | $292.00M | $150.00M |
| Net Income | $815.00M | $486.00M | $335.00M | $219.00M | $25.00M |
| Net Margin | 14.7% | 10.1% | 7.4% | 5.6% | 0.7% |
| EPS | $3.68 | $2.20 | $1.52 | $1.00 | $0.11 |
Company Overview
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AKBLFBeat Rate
78%
Last 18 quarters
Avg Surprise
+708.7%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$0.22
Q4 2025
EPS Surprise History
Q1 24
+525.0%
$0.70vs$0.11
Q2 24
+10.0%
$1.10vs$1.00
Q3 24
+44.4%
$0.13vs$0.09
Q4 24
+744.6%
$1.00vs$0.12
Q1 25
-22.0%
$0.11vs$0.14
Q2 25
+20.4%
$0.24vs$0.20
Q3 25
-7.6%
$0.19vs$0.20
Q4 25
+40.0%
$0.22vs$0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 17, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $0.16 | $0.22 | +40.0% | ✓ BEAT |
Q3 2025 | Aug 21, 2025 | $0.20 | $0.19 | -7.6% | ✗ MISS |
Q2 2025 | May 6, 2025 | $0.20 | $0.24 | +20.4% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $0.14 | $0.11 | -22.0% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $0.12 | $1.00 | +744.6% | ✓ BEAT |
Q3 2024 | Aug 23, 2024 | $0.09 | $0.13 | +44.4% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $1.00 | $1.10 | +10.0% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.11 | $0.70 | +525.0% | ✓ BEAT |
Q4 2023 | Nov 15, 2023 | $0.05 | $0.50 | +864.3% | ✓ BEAT |
Q3 2023 | Aug 24, 2023 | $0.04 | $0.30 | +689.7% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $0.07 | $0.70 | +915.4% | ✓ BEAT |
Q1 2023 | Feb 3, 2023 | $0.04 | $0.35 | +700.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $0.01 | $0.23 | +1836.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.00 | $0.19 | +4678.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $0.07 | $0.74 | +895.4% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $0.03 | $0.35 | +1112.8% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $0.19 | $0.17 | -10.5% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.02 | $-0.09 | -280.1% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about AKBLF
What is AKBLF's current stock price?
ALK-Abelló A/S (AKBLF) is currently trading at $35.45 per share. The stock has moved -1.92% today.
What is the analyst price target for AKBLF?
No analyst price targets are currently available for this stock.
What sector is ALK-Abelló A/S in?
ALK-Abelló A/S operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is AKBLF's market cap?
ALK-Abelló A/S has a market capitalization of $7.14 billion, making it a mid-cap company.
Does AKBLF pay dividends?
No, ALK-Abelló A/S does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCAMRF
Camurus AB (publ)
$64.22
Mkt Cap: $3.8B
CLCGY
Clicks Group Limited
$39.86
Mkt Cap: $4.7B
CSMYF
COSMOS Pharmaceutical Corporation
$48.27
Mkt Cap: $3.8B
FLMNY
Fielmann AG
$11.75
Mkt Cap: $4.9B
GNGBF
Getinge AB (publ)
$22.10
Mkt Cap: $5.6B
GNNSF
Genscript Biotech Corporation
$2.12
Mkt Cap: $4.6B
INCPF
InnoCare Pharma Limited
$2.13
Mkt Cap: $3.2B
LABFF
Laboratorios Farmaceuticos Rovi, S.A.
$90.61
Mkt Cap: $4.6B
SHJBF
Shanghai Junshi Biosciences Co., Ltd.
$2.99
Mkt Cap: $4.1B
ZLDPF
Zealand Pharma A/S
$74.58
Mkt Cap: $5.2B
Explore stocks similar to AKBLF for comparison